Company: INCR
Filing Date: 2025-05-01
Form Type: 20-F
Source: 0001641172-25-007971
Chunk: 52

Company: Intercure Ltd.
Filing Date: 2025-05-01
Form: 20-F
Item: Item 4
Chunk 52
---

ITEM    INFORMATION  
 4.    ON THE COMPANY
---------------------

A.               History            
     and Development of the Company.
------------------------------------
 
InterCure Ltd. is an Israeli public corporation incorporated in November 1994 under the Israeli Companies Ordinance [New Version] 5743-1983. Our shares are listed for trading on the Nasdaq under the symbol “INCR” and on the TASE under the symbol “INCR”. Our principal executive offices are located at 85 Medinat ha Yehudim Street, 4676670 Israel. Our telephone number in Israel is +972 77 460 5012. Our website address is http://www.intercure.co. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this Annual Report, and the reference to our website in this Annual Report is an inactive textual reference only. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our filings with the SEC will also be available to the public through the SEC’s website at www.sec.gov.
 
Previously, our shares were listed on the Toronto Stock Exchange (“TSX”) under the symbol “INCR:U”. In August 2023, following approval by the TSX of our request to delist our ordinary shares from trading on the TSX, our shares were delisted from trading on the TSX.
 
We currently own all of the issued and outstanding shares of Canndoc, Pharmazone, Leon Pharm and Cannolam and other holdings in additional pharmacies and trade houses.
 
We (more specifically through Canndoc) are a pioneer in the production (including the breeding, cultivating and processing), manufacturing and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use. For more than 17 years, we have been a leader in the licensed production and distribution of cannabis and cannabis-based products throughout Israel, one of the first countries with a governmentally-sanctioned regime for the production, manufacturing and distribution of cannabis for medical use. Our goal is to be a global leader in the production and distribution of high-quality pharmaceutical-grade cannabis-based branded products to patients in all territories that permit and regulate the distribution of pharmaceutical-grade cannabis, including Israel, the European Union and Australia.
 
Notwithstanding our plans for growth, we will operate only in countries where cannabis may be legally used for medical purposes and permitted under all applicable laws